- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06392386
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
April 26, 2024 updated by: argenx
An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis
The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to <18 years.
The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study.
Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study.
At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sabine Coppieters, MD
- Phone Number: 857-350-4834
- Email: clinicaltrials@argenx.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The participant (and/or their legally authorized representative) understands the requirements of the study and is capable of providing written informed consent/assent and complying with protocol requirements
- The participant is aged 2 to <18 years at the time of informed consent/assent
- The participant has been diagnosed with generalised Myasthenia Gravis that is supported by a physical examination and confirmed seropositivity for anti-acetylcholine receptor antibodies
- The participant has had an unsatisfactory response to immunosuppressants, corticosteroids, or acetylcholinesterase inhibitors but is on stable concomitant MG therapy. If receiving corticosteroids and/or immunosuppressants, must be on a stable dose for ≥1 month before screening
- The participant agrees to use birth control consistent with local regulations and people of child-bearing potential must have a negative blood pregnancy test at screening and a negative urine pregnancy test before receiving the study drug
Exclusion Criteria:
- Is a female adolescent of child-bearing potential who is pregnant and/or lactating or intends to become pregnant during their participation in the study
- Has worsening muscle weakness secondary to a concurrent infection or as a result of a medication
- Has a documented lack of clinical response to plasma exchange (PLEX)
- Received a live or live-attenuated vaccine within <4 weeks before screening
- Received a thymectomy within 3 months before screening or is planning to get a thymectomy during their participation in the study
- Has a known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of generalised Myasthenia Gravis or puts the participant at undue risk
- History of malignancy, cancer, unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years. Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological findings of prostate cancer
- Clinically significant active infection that is not sufficiently resolved in the investigator's opinion or positive serum test at screening for active infection with any of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), HIV
- Has a positive PCR test for SARS-CoV-2 at screening
- Has/had a clinically significant disease, had recent major surgery (within 3 months of screening) or intends to have major surgery during the study, or has/had any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk
- Has received a different study drug in another clinical study within <12 before screening
- Is currently participating in another interventional clinical study
- Has previously participated in an efgartigimod clinical study and received at least one dose of study drug
- Has a known hypersensitivity to study drug or any of its excipients
- Has a history of or current episode of alcohol, drug, or medication abuse as assessed by the investigator
- Use of some medications before screening (more information is found in the protocol)
The complete list of exclusion criteria can be found in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Efgartigimod PH20 SC
Participants aged 12 to <18 years receiving efgartigimod PH20 SC treatment
|
Subcutaneous injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysis
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysis
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Severity of adverse events (AEs)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Severity of serious adverse events (SAEs)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Incidence of adverse events of special interest (AESI)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Severity of adverse events of special interest (AESI)
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
|
Efgartigimod serum concentrations
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Absolute values of total Immunoglobulin G (IgG) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Change from baseline values of total Immunoglobulin G (IgG) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Percentage change from baseline values of total Immunoglobulin G (IgG) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Absolute values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Percentage change from baseline values of anti-acetylcholine receptor antibodies (AChR-Ab) from blood samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Incidence of anti-drug antibodies (ADAs) against efgartigimod in serum samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Prevalence of anti-drug antibodies (ADAs) against efgartigimod in serum samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Incidence of antibodies against rHuPH20 in serum samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Prevalence of antibodies against rHuPH20 in serum samples
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Absolute value of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score, appropriate for pediatric use
Time Frame: Up to 12 weeks
|
Minimum value: 0 (no impairment); Maximum value: 24 (highest impairment)
|
Up to 12 weeks
|
Change from baseline of total Myasthenia Gravis Activity of Daily Living (MG-ADL) score, appropriate for pediatric use
Time Frame: Up to 12 weeks
|
Minimum value: 0 (no impairment); Maximum value: 24 (highest impairment)
|
Up to 12 weeks
|
Absolute value of Quantitative Myasthenia Gravis (QMG) score
Time Frame: Up to 12 weeks
|
Minimum value: 0 (no impairment); Maximum value: 39 (most severe impairment)
|
Up to 12 weeks
|
Change from baseline of Quantitative Myasthenia Gravis (QMG) score
Time Frame: Up to 12 weeks
|
Minimum value: 0 (no impairment); Maximum value: 39 (most severe impairment)
|
Up to 12 weeks
|
Absolute value of EuroQoL 5 Dimensions Youth (EQ-5D-Y) score
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Change from baseline value of EuroQoL 5 Dimensions Youth (EQ-5D-Y) score
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Change from baseline value of Neuro-QoL Pediatric Fatigue Score
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Change from baseline value of Clinical Global Impression of Improvement (CGI-I)
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
|
Changes in protective antibody titers to vaccines
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 31, 2024
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
April 26, 2024
First Submitted That Met QC Criteria
April 26, 2024
First Posted (Actual)
April 30, 2024
Study Record Updates
Last Update Posted (Actual)
April 30, 2024
Last Update Submitted That Met QC Criteria
April 26, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
Other Study ID Numbers
- ARGX-113-2207
- 2023-506159-12-00 (Ctis)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenia Gravis, GeneralizedUnited States
-
Cabaletta BioNot yet recruitingGeneralized Myasthenia Gravis (gMG)
-
argenxRecruiting
-
Kyverna TherapeuticsNot yet recruitingGeneralized Myasthenia Gravis | Myasthenia Gravis
-
UCB Biopharma SRLNot yet recruitingGeneralized Myasthenia Gravis
-
Tang-Du HospitalRecruitingMyasthenia Gravis, GeneralizedChina
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia Gravis | gMGSpain, Italy, United States, France, Switzerland, Serbia, Japan, Netherlands
-
argenxRecruitingGeneralized Myasthenia GravisUnited States, Netherlands, Belgium, Poland, United Kingdom
Clinical Trials on Efgartigimod PH20 SC
-
argenxActive, not recruitingPrimary Immune ThrombocytopeniaUnited States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
-
argenxRecruitingThyroid Eye DiseaseUnited States
-
argenxRecruitingThyroid Eye DiseaseUnited States
-
argenxCompleted
-
argenxRecruitingPrimary Immune ThrombocytopeniaUnited States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
-
argenxCompletedGeneralized Myasthenia GravisSpain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
-
argenxRecruitingGeneralized Myasthenia GravisUnited States, Netherlands, Belgium, Poland, United Kingdom
-
argenxActive, not recruitingGeneralized Myasthenia GravisUnited States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
-
argenxCompleted
-
argenxActive, not recruitingChronic Inflammatory Demyelinating Polyneuropathy (CIDP)United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey